Drug intelligence / Profile preview

VYR-201

Development stage: Preclinical
Lead developer: Vyripharm International
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VYR-201 is a precision imaging diagnostic agent currently in preclinical development by Vyripharm International. It is specifically designed for the detection and monitoring of Alzheimer's disease. As part of Vyripharm's pipeline of integrated theranostic solutions, VYR-201 is intended to provide high-resolution molecular imaging to identify pathological markers associated with neurodegeneration, facilitating earlier diagnosis and more accurate tracking of disease progression.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on VYR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-201.

Explore the full profile